Eupraxia Pharmaceuticals (EPRX) Treasury Shares (2022 - 2025)
Eupraxia Pharmaceuticals' (EPRX) quarterly Treasury Shares came in at $8.0 million in Q4 2025, down 30.22% on a QoQ basis from $11.5 million in Q4 2022.
Eupraxia Pharmaceuticals (EPRX) Treasury Shares (2022 - 2025) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 2 years of Treasury Shares data on file, last reported at $8.0 million in Q4 2025.
- On a quarterly basis, Treasury Shares changed N/A year-over-year to $8.0 million in Q4 2025; TTM through Dec 2025 was $8.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $8.0 million, changed N/A from the prior year.
- Treasury Shares for Q4 2025 stood at $8.0 million, down from $11.5 million in the prior quarter.
- Over the last five years, Treasury Shares for EPRX reached as high as $11.5 million in Q4 2022 and fell as low as $8.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -21,709.08 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 265,401.92 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 34.70 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 5.14 Mn |
| 10 | Eupraxia Pharmaceuticals | 329.50 Mn | 329.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.03 Mn |
| Dec 31, 2025 | 8.03 Mn |
| Dec 31, 2022 | 11.50 Mn |
| Dec 31, 2022 | 11.50 Mn |